Down-regulation of miR-517a and miR-517c promotes proliferation of hepatocellular carcinoma cells via targeting Pyk2

Cancer Letters

Volumn 329, Issue 2, 2013, Pages 164-173

  Liu, Rui Fang ^a,b   Xu, Xiao ^a,b   Huang, Jian ^a,b   Fei, Qian Lan ^b   Chen, Fei ^b   Li, Yan Dong ^b   Han, Ze Guang ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

Author keywords

5 Aza 2' deoxycytidine; Cell proliferation; G2 M arrest; Hepatocellular carcinoma; Trichostatin A

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; FOCAL ADHESION KINASE 2; MICRORNA; MICRORNA 517A; MICRORNA 517C; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; EPIGENETICS; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN RNA BINDING; PROTEIN TARGETING;

AZACITIDINE; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DNA MODIFICATION METHYLASES; DOWN-REGULATION; FOCAL ADHESION KINASE 2; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LIVER NEOPLASMS; MICRORNAS; MULTIGENE FAMILY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA INTERFERENCE; TRANSCRIPTOME;

EID: 84872494563     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.10.027     Document Type: Article

References (47)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J., Bell B.P. The contributions of Hepatitis B virus and Hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 2006, 45:529-538.
3. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
4. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
5. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
6. Wahid F., Shehzad A., Khan T., Kim Y.Y. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim. Biophys. Acta 1803, 2010:1231-1243.
7. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
8. Nilsen T.W. Mechanisms of microRNA-mediated gene regulation in animal cells. Trends Genet. 2007, 23:243-249.
9. Kloosterman W.P., Plasterk R.H. The diverse functions of microRNAs in animal development and disease. Dev. Cell 2006, 11:441-450.
10. Ventura A., Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell 2009, 136:586-591.
11. Shi X.B., Tepper C.G., deVere White R.W. Cancerous miRNAs and their regulation. Cell Cycle 2008, 7:1529-1538.
12. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., Wojcik S.E., Aqeilan R.I., Zupo S., Dono M., Rassenti L., Alder H., Volinia S., Liu C.G., Kipps T.J., Negrini M., Croce C.M. MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA 2005, 102:13944-13949.
13. Xu T., Zhu Y., Xiong Y., Ge Y.Y., Yun J.P., Zhuang S.M. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 2009, 50:113-121.
14. Sharma S., Kelly T.K., Jones P.A. Epigenetics in cancer. Carcinogenesis 2010, 31:27-36.
15. Iacobuzio-Donahue C.A. Epigenetic changes in cancer. Annu. Rev. Pathol. 2009, 4:229-249.
16. Bueno M.J., Perez de Castro I., Gomez de Cedron M., Santos J., Calin G.A., Cigudosa J.C., Croce C.M., Fernandez-Piqueras J., Malumbres M. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 2008, 13:496-506.
17. Lehmann U., Hasemeier B., Christgen M., Muller M., Romermann D., Langer F., Kreipe H. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J. Pathol. 2008, 214:17-24.
18. Bortolin-Cavaille M.L., Dance M., Weber M., Cavaille J. C19MC microRNAs are processed from introns of large Pol-II, non-protein-coding transcripts. Nucleic Acids Res. 2009, 37:3464-3473.
19. Tsai K.W., Kao H.W., Chen H.C., Chen S.J., Lin W.C. Epigenetic control of the expression of a primate-specific microRNA cluster in human cancer cells. Epigenetics 2009, 4:587-592.
20. Toffanin S., Hoshida Y., Lachenmayer A., Villanueva A., Cabellos L., Minguez B., Savic R., Ward S.C., Thung S., Chiang D.Y., Alsinet C., Tovar V., Roayaie S., Schwartz M., Bruix J., Waxman S., Friedman S.L., Golub T., Mazzaferro V., Llovet J.M. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 2011.
21. Yoshitomi T., Kawakami K., Enokida H., Chiyomaru T., Kagara I., Tatarano S., Yoshino H., Arimura H., Nishiyama K., Seki N., Nakagawa M. Restoration of miR-517a expression induces cell apoptosis in bladder cancer cell lines. Oncol. Rep. 2011.
22. Varkonyi-Gasic E., Wu R., Wood M., Walton E.F., Hellens R.P. Protocol: a highly sensitive RT-PCR method for detection and quantification of microRNAs. Plant Methods 2007, 3:12.
23. Schmittgen T.D., Lee E.J., Jiang J., Sarkar A., Yang L., Elton T.S., Chen C. Real-time PCR quantification of precursor and mature microRNA. Methods 2008, 44:31-38.
24. Saito Y., Liang G., Egger G., Friedman J.M., Chuang J.C., Coetzee G.A., Jones P.A. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006, 9:435-443.
25. Sun C.K., Ng K.T., Sun B.S., Ho J.W., Lee T.K., Ng I., Poon R.T., Lo C.M., Liu C.L., Man K., Fan S.T. The significance of proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma progression and recurrence. Br. J. Cancer 2007, 97:50-57.
26. Sun C.K., Man K., Ng K.T., Ho J.W., Lim Z.X., Cheng Q., Lo C.M., Poon R.T., Fan S.T. Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation. Carcinogenesis 2008, 29:2096-2105.
27. Zhang X., Xu L.H., Yu Q. Cell aggregation induces phosphorylation of PECAM-1 and Pyk2 and promotes tumor cell anchorage-independent growth. Mol Cancer 2010, 9:7.
28. Dal Cin P., Sneyers W., Aly M.S., Segers A., Ostijn F., Van Damme B., Van Den Berghe H. Involvement of 19q13 in follicular thyroid adenoma. Cancer Genet. Cytogenet. 1992, 60:99-101.
29. Belge G., Rippe V., Meiboom M., Drieschner N., Garcia E., Bullerdiek J. Delineation of a 150-kb breakpoint cluster in benign thyroid tumors with 19q13.4 aberrations. Cytogenet. Cell Genet. 2001, 93:48-51.
30. Meiboom M., Belge G., Bol S., El-Aouni C., Schoenmakers E.F., Bullerdiek J. Does conventional cytogenetics detect the real frequency of 19q13 aberrations in benign thyroid lesions? A survey of 38 cases. Cancer Genet. Cytogenet. 2003, 146:70-72.
31. Li M., Lee K.F., Lu Y., Clarke I., Shih D., Eberhart C., Collins V.P., Van Meter T., Picard D., Zhou L., Boutros P.C., Modena P., Liang M.L., Scherer S.W., Bouffet E., Rutka J.T., Pomeroy S.L., Lau C.C., Taylor M.D., Gajjar A., Dirks P.B., Hawkins C.E., Huang A. Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell 2009, 16:533-546.
32. Toffanin S., Hoshida Y., Lachenmayer A., Villanueva A., Cabellos L., Minguez B., Savic R., Ward S.C., Thung S., Chiang D.Y., Alsinet C., Tovar V., Roayaie S., Schwartz M., Bruix J., Waxman S., Friedman S.L., Golub T., Mazzaferro V., Llovet J.M. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 2011, 140:1618-1628. e1616.
33. Kasinski A.L., Slack F.J. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 2011, 11:849-864.
34. Rajaram V., Knezevich S., Bove K.E., Perry A., Pfeifer J.D. DNA sequence of the translocation breakpoints in undifferentiated embryonal sarcoma arising in mesenchymal hamartoma of the liver harboring the t(11;19)(q11;q13.4) translocation. Genes Chromosom. Cancer 2007, 46:508-513.
35. Rakheja D., Margraf L.R., Tomlinson G.E., Schneider N.R. Hepatic mesenchymal hamartoma with translocation involving chromosome band 19q13.4: a recurrent abnormality. Cancer Genet. Cytogenet. 2004, 153:60-63.
36. Mascarello J.T., Krous H.F. Second report of a translocation involving 19q13.4 in a mesenchymal hamartoma of the liver. Cancer Genet. Cytogenet. 1992, 58:141-142.
37. Hearle N., Lucassen A., Wang R., Lim W., Ross F., Wheeler R., Moore I., Shipley J., Houlston R. Mapping of a translocation breakpoint in a Peutz-Jeghers hamartoma to the putative PJS locus at 19q13.4 and mutation analysis of candidate genes in polyp and STK11-negative PJS cases. Genes Chromosom. Cancer 2004, 41:163-169.
38. Fornari F., Milazzo M., Chieco P., Negrini M., Marasco E., Capranico G., Mantovani V., Marinello J., Sabbioni S., Callegari E., Cescon M., Ravaioli M., Croce C.M., Bolondi L., Gramantieri L. In hepatocellular carcinoma miR-519d is upregulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. J. Pathol. 2012.
39. Abdelmohsen K., Kim M.M., Srikantan S., Mercken E.M., Brennan S.E., Wilson G.M., Cabo R., Gorospe M. MiR-519 suppresses tumor growth by reducing HuR levels. Cell Cycle 2010, 9:1354-1359.
40. Abdelmohsen K., Srikantan S., Kuwano Y., Gorospe M. MiR-519 reduces cell proliferation by lowering RNA-binding protein HuR levels. Proc. Natl. Acad. Sci. USA 2008, 105:20297-20302.
41. Cui W., Zhang Y., Hu N., Shan C., Zhang S., Zhang W., Zhang X., Ye L. MiRNA-520b and miR-520e sensitize breast cancer cells to complement attack via directly targeting 3'UTR of CD46. Cancer Biol. Ther. 2010, 10:232-241.
42. Wu S., Huang S., Ding J., Zhao Y., Liang L., Liu T., Zhan R., He X. Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3' untranslated region. Oncogene 2010, 29:2302-2308.
43. Huang Q., Gumireddy K., Schrier M., le Sage C., Nagel R., Nair S., Egan D.A., Li A., Huang G., Klein-Szanto A.J., Gimotty P.A., Katsaros D., Coukos G., Zhang L., Pure E., Agami R. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat. Cell Biol. 2008, 10:202-210.
44. Yang K., Handorean A.M., Iczkowski K.A. MicroRNAs 373 and 520c are downregulated in prostate cancer, suppress CD44 translation and enhance invasion of prostate cancer cells in vitro. Int. J. Clin. Exp. Pathol. 2009, 2:361-369.
45. Keklikoglou I., Koerner C., Schmidt C., Zhang J.D., Heckmann D., Shavinskaya A., Allgayer H., Guckel B., Fehm T., Schneeweiss A., Sahin O., Wiemann S., Tschulena U. MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kappaB and TGF-beta signaling pathways. Oncogene 2011.
46. Hodges R.R., Horikawa Y., Rios J.D., Shatos M.A., Dartt D.A. Effect of protein kinase C and Ca(2+) on p42/p44 MAPK, Pyk2, and Src activation in rat conjunctival goblet cells. Exp. Eye Res. 2007, 85:836-844.
47. Sorokin A., Kozlowski P., Graves L., Philip A. Protein-tyrosine kinase Pyk2 mediates endothelin-induced p38 MAPK activation in glomerular mesangial cells. J. Biol. Chem. 2001, 276:21521-21528.